Steven Kaplan

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Andrea Ardizzoni, H. Hansen, P Dombernowsky et al. · Journal of Clinical Oncology · 1997 · 481 citations

Medicine, Oncology, Pharmacology +14

Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)

Thomas Cerny, Steven Kaplan, N. Pavlidis et al. · British Journal of Cancer · 1994 · 161 citations · Full text

Medicine, Oncology, Pharmacology +10

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group

Steinar Aamdal, Ingmar Wolff, Steven Kaplan et al. · European Journal of Cancer · 1994 · 82 citations

Medicine, Oncology, Pharmacology +12

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation

Ian Judson, T. Cerny, Ron Epelbaum et al. · Annals of Oncology · 1997 · 54 citations · Full text

Medicine, Oncology, Cancer Pharmacology +9

Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results

Naeem Bhojani, Mo Bidair, Eugene V. Kramolowsky et al. · The Journal of Urology · 2023 · 50 citations · Full text

Medicine, Surgery, Urology +17